David L Bajor

8PUBLICATIONS
39CO-AUTHORS
Neurology and neuromuscular diseasesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 24, 2022
Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.

Amr Mohamed, Asfar S Azmi, Sylvia L Asa

|May 02, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.

Diwakar Davar, Roberta Zappasodi, Hong Wang

|Nov 06, 2021
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial.

Tithi Biswas, Afshin Dowlati, Charles A Kunos

|Oct 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Christos Fountzilas, David L Bajor, Sarbajit Mukherjee

|Jun 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Katelyn T Byrne, Courtney B Betts, Rosemarie Mick

|Jun 01, 2021
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014.

Aman Opneja, Gino Cioffi, Asrar Alahmadi

Pageof 2

Frequent Collaborators

2 joint publications

Jill S Barnholtz-Sloan

1 joint publications

Diwakar Davar

1 joint publications

Roberta Zappasodi

1 joint publications

Hong Wang